Amneal Pharmaceuticals (NYSE:AMRX) was downgraded by analysts at Svb Leerink from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Thursday, Briefing.com Automated Import reports.
AMRX has been the subject of a number of other research reports. SunTrust Banks reiterated a “buy” rating and issued a $5.00 price objective on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Guggenheim started coverage on shares of Amneal Pharmaceuticals in a research report on Thursday, September 12th. They issued a “sell” rating and a $2.50 price objective for the company. Raymond James downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the stock from $13.00 to $8.50 in a research report on Wednesday, July 10th. BMO Capital Markets decreased their price objective on shares of Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating for the company in a research report on Tuesday, August 6th. Finally, ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $9.00.
NYSE AMRX opened at $2.76 on Thursday. The company has a market capitalization of $1.02 billion, a PE ratio of 2.91, a P/E/G ratio of 0.98 and a beta of 1.48. The company has a fifty day moving average of $3.12 and a 200 day moving average of $5.49. Amneal Pharmaceuticals has a 1 year low of $2.27 and a 1 year high of $21.22. The company has a debt-to-equity ratio of 3.66, a current ratio of 2.17 and a quick ratio of 1.41.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.09). The business had revenue of $378.30 million for the quarter, compared to analyst estimates of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The company’s revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 earnings per share. Research analysts expect that Amneal Pharmaceuticals will post 0.5 earnings per share for the current year.
In related news, SVP Pradeep Bhadauria purchased 30,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $2.41 per share, for a total transaction of $72,300.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ted C. Nark purchased 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were bought at an average price of $2.39 per share, with a total value of $119,500.00. The disclosure for this purchase can be found here. 25.92% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AMRX. Tower Research Capital LLC TRC grew its stake in Amneal Pharmaceuticals by 790.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,766 shares of the company’s stock valued at $56,000 after acquiring an additional 6,894 shares in the last quarter. Bank of Montreal Can grew its stake in Amneal Pharmaceuticals by 87.5% during the 2nd quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock valued at $60,000 after acquiring an additional 3,954 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Amneal Pharmaceuticals by 1,176.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 32,798 shares of the company’s stock valued at $94,000 after acquiring an additional 30,228 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Amneal Pharmaceuticals by 12,036.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 39,445 shares of the company’s stock valued at $114,000 after acquiring an additional 39,120 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at about $177,000. Hedge funds and other institutional investors own 35.01% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.